AESARA Europe

Preparation

  • European Landscape Assessment
  • HTA Decision Analysis
  • Payer Research and Advisory Boards
  • EU Joint Scientific Consultation
  • Key Country Market Insights
  • EU JCA PICO prediction

Strategy

  • European HTA, price & reimbursement strategy
  • Lifecycle Management (LCM) Strategy
  • Value Story & Message Development
  • Evidence Gap Analysis
  • Evidence Generation Planning (incl. RWE & PLEG)
  • Value-based Price Potential
  • EU HTA/JCA Strategy
  • EU JCA process & governance design

Execution

  • EU JCA Dossier development
  • Country HTA Submissions
  • European Launch Management
  • Value Communications

Questions we answer

Is it worth launching your latest asset in Europe?
US and global biotechs come to AESARA Europe for expert, evidence-based, go/no-go market access advice
What should you invest in Europe – and when?
US and global biotechs hire AESARA Europe for asset due diligence, value-based pricing, and European market access infrastructure build
Will European payers value your medical innovation?
US and global biotechs use AESARA’s European market access industry veterans to optimise their value evidence and product value propositions for European HTA
How should you best structure and sequence your European HTA submissions for strategic impact and operational efficiency?
US and global biotechs use AESARA's European and in-country experts to plan and execute successful HTA and pricing and reimbursement submissions
What value evidence will European HTA bodies need to see in support of your value story, target population, & price?
Global biopharma companies trust AESARA's insight and experience to test and optimise value propositions and value evidence plans, for European HTA and reimbursement success
How should we best prepare for the new, centralised, European HTA?​
Biotech and pharma innovators use AESARA Europe’s unique blend of HTA strategy and management consulting professionals to build structures, processes, governance, and submissions for EU Joint Clinical Assessment​

Strategy leaders

Kate Burslem, MSc

has over 20 years’ experience in the healthcare field in Europe and the US. She joins AESARA from AbbVie, where she most recently led the global HEOR team supporting AbbVie’s Toxin Therapeutic & Eyecare portfolios, having previously held leadership positions in the Neuroscience & Gastrointestinal therapeutic areas. Before joining AbbVie, Kate held positions of increasing responsibility in HEOR at Boehringer Ingelheim, within both the US and UK affiliates. Prior to joining the pharmaceutical industry, Kate worked as a Technical Analyst at the UK’s National Institute for Health & Care Excellence.  She began her career in employee benefits consulting, where her work on international medical insurance plan design inspired her to go back to school and study health economics.

Kate has a strategic mindset, coupled with strong analytical skills in the key HEOR disciplines of real-world evidence, economic modeling and patient-reported outcomes. She enjoys developing value and access strategies at all stages of the product lifecycle and fostering alignment across multi-disciplinary teams to achieve a common goal. Her career has spanned a broad range of therapeutic areas including immunology, oncology, neuroscience, respiratory, cardiovascular and diabetes.

Catherine Chamoux, PhD

has international experience acquired over thirty+ years in the pharma industry in medium-sized and large companies. She holds a PhD in Pharmacy and a Masters of Public Health from Sciences Po, Paris. She is an expert in Market Access for innovative drugs.

As a member of the leadership team of the French affiliate of a leading US biotech for 15 years, she helped establish & develop the company locally, directly negotiated product prices & access conditions, developed relationships with regulators, payors and KOLs. She also actively participated in the evidence generation and early access program strategies for our innovative therapies, including orphan drug products, highlighting the unmet needs and the products’ unique attributes.

She also has strong pan-European experience in Market Access, having most recently led the Market Access Excellence function for Europe, creating common understanding, tools, measures and co-operation between countries.

Case studies

European Sequencing Strategy

A US-headquartered specialty biotech acquired an innovative oncology asset with multiple indications of interest…

European HTA Submission Programme

Planning and execution of health technology assessment (HTA), price, reimbursement submissions in European markets…

European Asset Due Diligence

Bringing European markets’ price, access and reimbursement insight to support global in-licensing decisions…

Conversations

Contact us

Fill out the form below, and we will be in touch shortly.